In­ter­cept scores a mixed win on NASH Phase III sweep­stakes, plans mar­ket­ing pitch

In­ter­cept Phar­ma­ceu­ti­cals says they’ve cleared one of the high bars on their Phase III NASH study of obeti­cholic acid (OCA), set­ting up a pi­o­neer­ing mar­ket­ing pitch in the com­ing months.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.